Over 3 million Aetna Medicare Advantage plan members nationwide will have access to Durolane, a single-injection hyaluronic acid-based joint-fluid treatment for patients with knee osteoarthritis pain.
Durolane is now one of two single-injection HA products under contract, according to a Dec. 6 press release from Bioventus.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
